Redeye updates its estimates and valuation after Vitec’s Q3 2025 report. EBITA missed our projection by c6%, with tough comparables for transaction-based recurring revenues throttling growth. However, we judge there are plenty of reasons to remain optimistic, and we expect investor sentiment to improve in 2026e.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/